enGene to host KOL webinar on high-risk NMIBC treatment decisions and LEGEND trial data
ENGN•enGene will host a webinar on Oct. 15, 2026, at 10:00 a.m. ET, featuring preclinical data and clinician discussion of treatment decisions for BCG-unresponsive, high-risk NMIBC with CIS.
1. Webinar agenda
The webinar agenda includes preclinical data supporting a polidocanol surfactant bladder rinse before intravesical detalimogene. Community clinicians David J. Cahn, MD, and Suzanne B. Merrill, MD, FACS, will discuss real-world treatment decisions using case studies.
